TROV : Summary for TrovaGene, Inc. - Yahoo Finance

U.S. Markets closed

TrovaGene, Inc. (TROV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.000.00 (0.00%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close2.00
Bid1.25 x 400
Ask2.75 x 100
Day's Range2.00 - 2.05
52 Week Range1.78 - 6.93
Avg. Volume303,318
Market Cap61.23M
PE Ratio (TTM)-1.54
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Accesswire25 days ago

    LD Micro Index Reconstitution as of February 1, 2017

    LOS ANGELES, CA / ACCESSWIRE / February 1, 2017 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2017. We believe that the existence of a true microcap ...

  • PR Newswirelast month

    Publication of Trovera™ KRAS Liquid Biopsy Test Demonstrates Clinical Utility in Advanced Cancers for Detection and Measurement of Therapeutic Response

    SAN DIEGO, Jan. 24, 2017 /PRNewswire/ -- Trovagene, Inc. (TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today announced the publication of study results in Clinical Cancer Research, demonstrating the analytical and clinical performance of Trovera™ urine and blood liquid biopsy tests to quantitatively assess KRAS mutations in patients with diverse advanced cancers.  This data was also featured as a presentation at the 2017 Gastrointestinal Cancers Symposium on January 21st in San Francisco, CA. The data demonstrate the clinical utility of Trovagene's proprietary mutation-enrichment technology to detect and quantitate KRAS mutations in urine and plasma from patients with advanced cancers. This was a blinded study with prospectively collected liquid biopsy samples, and archived tissue samples with known KRAS mutation status, from 71 patients with diverse advanced cancers.

  • PR Newswirelast month

    Trovagene Announces Broadening Network of Commercial Distributors

    SAN DIEGO, Jan. 12, 2017 /PRNewswire/ -- Trovagene, Inc. (TROV), a developer of circulating tumor DNA (ctDNA) technologies, today announced that it has signed agreements with seven strategic partners across Europe and the Middle East for commercialization of the Trovera™ liquid biopsy tests.  This milestone marks the first wave of international distribution agreements for Trovagene's CLIA based liquid biopsy tests for urine and blood samples. The initial partners will introduce Trovagene's liquid biopsy tests to physicians, laboratories and cancer centers in key regional markets.  In addition, these partners will have early access to Trovagene's research use only liquid biopsy kits and systems to distribute to clinical research facilities in Europe, Middle East, Africa and Asia. "We are excited to announce that physicians and patients in these international markets now have access to our industry leading laboratory developed tests for EGFR, KRAS, and BRAF mutations in urine and blood," said Bill Welch, Chief Executive Officer of Trovagene.